ClinicalTrials.gov record NCT07065747

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 16, 2026

Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

Healthy volunteersAcceptedPeople who do not have the condition being studied who are allowed to take part. Some studies include both people with the condition and healthy volunteers; others may enrol only healthy volunteers.

Age5 years old to 85 years old

SexAll

LocationUnited States

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This observational study looks at whether high-resolution optical coherence tomography (OCT) can be used to identify, count, and describe inflammatory cells and related signals in the eye. People are grouped as eyes with active uveitis, eyes with posterior vitreous detachment (floaters), or healthy control eyes. OCT images will be analyzed by computer algorithms and compared with standard clinical slit-lamp grading.

What it is studying. The study tests if OCT images can objectively identify and quantify anterior chamber cells, keratic precipitates, vitreous cells, and measures of flare or vitreous haze, and how those OCT-derived measures relate to clinical slit-lamp grading systems (SUN and NEI) and diagnostic categories of uveitis.

What the researchers hope to learn. To develop an unbiased, standard method using OCT to count and categorize inflammatory cells and signals in anterior uveitis; to correlate OCT measurements with existing clinical grading systems (SUN and NEI); and to describe keratic precipitate appearance and vitreous findings across diagnostic categories.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

The goal of this study is to determine if it's possible to use a high resolution imaging device called optical coherence tomography (OCT) to develop an unbiased, standard method of counting and categorizing the various types of cells and proteins found in an eye condition called anterior uveitis. Anterior uveitis is a type of inflammation in the eye that can be caused by many different diseases of the body.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

Uveitis Group: Eyes with active intraocular inflammation and a clinical diagnose of spondyloarthritis/HLA-B27 associated anterior uveitis, Juvenile Idiopathic Arthritis (JIA) associated chronic anterior uveitis, Herpes Simplex Virus (HSV) anterior uveitis, Birdshot chorioretinitis, Behcet disease uveitis, sarcoidosis associated uveitis, uveitis of any additional type, or uveitis masquerade.
Posterior Vitreous Detachment Group: Eyes with vitreous floaters and posterior vitreous detachment (PVD).
Healthy/Control Group: Healthy eyes with no history of uveitis, PVD, or previous eye surgery.

Exclusion criteria

Inability to give informed consent.
Inability to maintain stable fixation for OCT imaging.
Inability to commit to required visits to complete the study.
Pregnancy and breastfeeding.

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants will attend a study visit in which the eye is imaged with high-resolution optical coherence tomography (OCT) and examined at the slit lamp by an eye doctor. OCT images will be analyzed by computer algorithms to identify and count anterior chamber cells, vitreous cells, keratic precipitates, and signal measures; clinicians will record comparative grading using standard scales (SUN and NEI). These measurements are collected as a cross-sectional assessment (Day 1). The registry record does not describe other tests or any invasive procedures.

How the study is structured. An observational, cross-sectional cohort study with three groups (Uveitis, Posterior Vitreous Detachment, and Healthy/Control). Participants have OCT imaging of the eye; attending physicians perform clinical slit-lamp grading. OCT images are analyzed by computer algorithms and compared to physician grading on the same day.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

The registry lists this study under Anterior Uveitis (AU); Birdshot Chorioretinitis; Behcet Disease; Herpes Simplex Virus; Juvenile Idiopathic Arthritis (JIA); Spondyloarthritis (SA); Sarcoidosis; Posterior Vitreous Detachment. Does it apply to my diagnosis?
This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The listed sites are in United States. Is any of them reachable for me, and does the study help with travel?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on Behçet's disease

This trial is also listed on this site under familial Mediterranean fever.

Clinical trials34 trials listed for Behçet's diseaseEvery trial the registry lists for Behçet's disease, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in Behçet's disease researchLatest monthly update: September 2026. Includes: Low-dose IL-2 trial. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: Sep 1, 2024
Primary completion: September 2026 (estimated)
Study completion: December 2026 (estimated)
Target enrollment: 125 participants (estimated)
Last updated on registry: Jul 17, 2025
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: Oregon Health and Science University
Principal investigator: David Huang, Professor
Oregon Health and Science University
Collaborators: National Eye Institute (NEI)

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Humberto Martinez, COT, MBA 📞 503-494-7712 ✉ martinhu@ohsu.edu
Denzil Romfh, OD 📞 503-494-4351 ✉ romfhd@ohsu.edu

Participating sites (1)

Casey Eye Institute - Oregon Health & Science UniversityRecruiting
Portland, Oregon, 97239 · United States

Terms used on this page · explanations by MedicalUpdates.ai

Control Group: The group the study treatment is compared with. It may receive a placebo, an existing treatment (active comparator), a sham procedure, or no intervention.
informed consent: The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials